By Elodie Vaz | Published on March 16, 2026 | 3 min read
Ovarian
cancer remains one of the most feared gynecological cancers, largely due to
late diagnosis and a strong tendency to develop therapeutic resistance. The
most common and aggressive form is high-grade serous ovarian cancer,
which often responds initially to chemotherapy but frequently becomes
refractory to treatment over time.
While immunotherapies,
particularly immune checkpoint inhibitors, have transformed the management of
several solid tumors, their effectiveness in ovarian cancer has been limited. One major
reason is that cancer cells actively reshape their immune microenvironment,
weakening the body's immune response and enabling tumors to evade immune
attack.
In this
context, a study conducted by researchers at the University of California
San Diego and published in the journal Cell in March 2026 proposes a
new therapeutic strategy aimed at reprogramming the interaction between
tumors and the immune system.
Understanding
how to reverse tumor-induced immunosuppression
The
objective of this research was to identify molecular mechanisms capable of
modifying communication between ovarian tumor cells and surrounding immune
cells in order to restore an effective immune response.
The
researchers focused on a key intracellular protein: focal adhesion kinase
(FAK). This kinase is frequently highly activated in ovarian cancers and
plays an important role in tumor progression.
According
to David D. Schlaepfer, senior author of the study and professor at the
UC San Diego School of Medicine, “our results reveal a previously unknown
lipid communication pathway between ovarian tumors and the immune system.”
He adds that “by inhibiting FAK, we can reprogram macrophages so that they
promote antitumor immunity rather than suppress it.”
An
experimental approach focused on cellular communication
To
investigate this mechanism, the researchers studied the consequences of blocking
FAK activity in ovarian tumor cells and examined how this inhibition
affected surrounding immune cells.
They
analyzed the molecular signals produced by tumor cells and how these signals
were detected by macrophages, key immune cells involved in regulating
inflammatory and immune responses.
Murine
models of ovarian cancer were also used to evaluate the therapeutic impact of a
strategy combining FAK inhibition, low-dose chemotherapy, and immunotherapy.
Macrophages
reprogrammed as antitumor allies
The results
showed that blocking FAK activity in tumor cells profoundly alters their
communication with the immune system. Under these conditions, cancer cells
release small lipid particles rich in omega-3 fatty acids, similar to
those found in fish oil.
These
particles are taken up by nearby macrophages, which interpret these lipids as
cellular signals. In response, macrophages adopt an antitumor phenotype
and begin producing the molecule CXCL13.
CXCL13 acts
as a chemotactic signal that attracts additional immune cells capable of
attacking cancer cells, thereby increasing immune infiltration within the
tumor microenvironment.
In mouse
models, the combination of a FAK inhibitor, low-dose chemotherapy, and
immunotherapy suppressed tumor growth, increased immune cell infiltration,
and prolonged survival.
A
promising therapeutic strategy
These
findings highlight a previously unknown mechanism linking tumor lipid
metabolism and immune microenvironment reprogramming. By transforming
macrophages from an immunosuppressive role to an immune-activating role, FAK
inhibition could overcome one of the major barriers to effective immunotherapy
in ovarian cancer.
Drugs
targeting FAK are already being evaluated in clinical trials for ovarian
cancer. The results of this study suggest that combining these agents with
certain chemotherapies and immunotherapies could significantly improve
therapeutic responses.
Although
further research and clinical trials are required, this strategy opens the door
to a new generation of treatments aimed not only at targeting the tumor itself
but also at reshaping its immune microenvironment. Such an approach
could ultimately benefit patients with ovarian cancer and potentially other
cancers characterized by strong tumor-induced immunosuppression.
Read next: TyG Index: a new ally against PCOS?
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of human.
